Compare SRPT & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | HURN |
|---|---|---|
| Founded | 1980 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2000 | 2004 |
| Metric | SRPT | HURN |
|---|---|---|
| Price | $22.03 | $158.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 29 | 5 |
| Target Price | $25.85 | ★ $204.40 |
| AVG Volume (30 Days) | ★ 2.9M | 263.2K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.99 | 1.34 |
| Revenue | ★ $2,198,237,000.00 | $1,699,143,000.00 |
| Revenue This Year | N/A | $11.80 |
| Revenue Next Year | N/A | $8.23 |
| P/E Ratio | ★ $7.22 | $119.28 |
| Revenue Growth | ★ 15.58 | 11.65 |
| 52 Week Low | $14.68 | $84.88 |
| 52 Week High | $25.32 | $186.78 |
| Indicator | SRPT | HURN |
|---|---|---|
| Relative Strength Index (RSI) | 72.39 | 62.22 |
| Support Level | $20.12 | $158.12 |
| Resistance Level | $23.71 | $174.50 |
| Average True Range (ATR) | 1.08 | 5.33 |
| MACD | 0.33 | -1.10 |
| Stochastic Oscillator | 90.82 | 71.20 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.